悦康药业
(688658)
| 流通市值：85.50亿 | | | 总市值：85.50亿 |
| 流通股本：4.50亿 | | | 总股本：4.50亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 556,037,071.94 | 2,446,086,968.93 | 1,759,106,131.97 | 1,167,382,036.87 |
| 营业收入 | 556,037,071.94 | 2,446,086,968.93 | 1,759,106,131.97 | 1,167,382,036.87 |
| 二、营业总成本 | 582,235,968.13 | 2,682,131,403.61 | 1,936,291,861.68 | 1,269,538,108.89 |
| 营业成本 | 239,489,908 | 1,218,344,224.54 | 889,487,883.35 | 588,714,164.95 |
| 税金及附加 | 8,620,113.51 | 38,416,344.43 | 28,423,444.71 | 18,639,263.21 |
| 销售费用 | 183,401,679.27 | 703,899,243.35 | 503,822,735.77 | 318,386,243.57 |
| 管理费用 | 55,179,083.47 | 266,972,832.16 | 187,706,427.97 | 133,280,166.95 |
| 研发费用 | 91,687,640.44 | 441,205,802.99 | 316,552,600.23 | 203,049,828.36 |
| 财务费用 | 3,857,543.44 | 13,292,956.14 | 10,298,769.65 | 7,468,441.85 |
| 其中:利息费用 | 4,323,557.13 | 21,653,299.28 | 16,572,381.33 | 11,337,095.89 |
| 其中:利息收入 | 636,539.35 | 8,857,163.49 | -6,487,974.16 | -4,033,697.21 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 1,349,550.61 | 6,040,391.9 | 301,842.59 | 37,997.51 |
| 加:投资收益 | 779,942 | 3,461,129.19 | 2,437,656.3 | 1,385,511.85 |
| 资产处置收益 | 283,271.88 | 924,147.58 | 3,106,247.76 | - |
| 资产减值损失(新) | -11,765,945.74 | -41,543,453.77 | -19,321,293.37 | -18,583,861.35 |
| 信用减值损失(新) | 715,949.93 | 3,621,536.25 | 6,993,424.2 | -746,336.36 |
| 其他收益 | 4,880,745.24 | 29,094,959.63 | 19,964,889.37 | 13,375,322.35 |
| 四、营业利润 | -29,955,382.27 | -234,445,723.9 | -163,702,962.86 | -106,687,438.02 |
| 加:营业外收入 | 29,867.8 | 1,580,712.41 | 678,922.28 | 645,207.8 |
| 减:营业外支出 | 636,333.12 | 4,187,444.36 | 1,787,262.69 | 1,212,289.93 |
| 五、利润总额 | -30,561,847.59 | -237,052,455.85 | -164,811,303.27 | -107,254,520.15 |
| 减:所得税费用 | 7,465,657.02 | 37,763,734.96 | -10,208,565.76 | -5,074,369.01 |
| 六、净利润 | -38,027,504.61 | -274,816,190.81 | -154,602,737.51 | -102,180,151.14 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -38,027,504.61 | -274,816,190.81 | -154,602,737.51 | -102,180,151.14 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -33,106,026.51 | -262,389,860.99 | -147,977,976.65 | -98,829,145.21 |
| 少数股东损益 | -4,921,478.1 | -12,426,329.82 | -6,624,760.86 | -3,351,005.93 |
| 扣除非经常损益后的净利润 | -37,344,424.7 | -287,945,988.91 | -167,500,357.17 | -108,465,246.01 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.07 | -0.59 | -0.33 | -0.22 |
| (二)稀释每股收益 | -0.07 | -0.59 | -0.33 | -0.22 |
| 八、其他综合收益 | - | -28,239.37 | - | - |
| 归属于母公司股东的其他综合收益 | - | -28,239.37 | - | - |
| 九、综合收益总额 | -33,106,026.51 | -274,844,430.18 | -154,602,737.51 | -102,180,151.14 |
| 归属于母公司股东的综合收益总额 | -33,106,026.51 | -262,418,100.36 | -147,977,976.65 | -98,829,145.21 |
| 归属于少数股东的综合收益总额 | - | -12,426,329.82 | -6,624,760.86 | -3,351,005.93 |
| 公告日期 | 2026-04-30 | 2026-03-21 | 2025-10-30 | 2025-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |